HOTH - Hoth Therapeutics updates on HT-002 in COVID-19 preclinical study

Hoth Therapeutics (HOTH) provides an update on preclinical study on HT-002 for the prevention and/or treatment of Sars-CoV-2, or COVID-19. There are three leading peptide candidates that have been optimized chemically to maximize the potential viral inhibition.One of the peptide candidates has demonstrated low level viral inhibition assay with no toxicity to the host cell. One or more of the optimized peptide candidates may be combined to achieve maximum viral inhibition. Peptide sequence modeling analysis supports that these optimized peptides could be effective against the emerging U.K. and South African SARS-CoV-2 strain variants. The research is being led by inventor Michael H. Peters, Ph.D., Professor, Department of Chemical and Life Science Engineering at Virginia Commonwealth University, College of Engineering.HOTH shares are up 2.7% premarket trading at $2.68.

For further details see:

Hoth Therapeutics updates on HT-002 in COVID-19 preclinical study